Two of Medtronic’s largest markets that have been struggling for quite some time were the very ones to show some improvement in the company’s first fiscal quarter earnings that it reported Tuesday. Medtronic CEO Omar Ishrak told analysts that both the U.S.implanted cardioverter defibrillator (ICD) market and the domestic Spine business showed signs of “signs of stabilization” in the quarter. In fact in the ICD division, Medtronic performed better than the market which declined 4 percent compared to the company whose U.S. ICD revenue fell only 3 percent, Ishrak noted.
